Skip to Content
How to talk to a doctor about advanced ovarian cancer >>

Sodium Iodide, i-123

Dosage Form: capsule

Indications and Usage for Sodium Iodide, i-123

Sodium Iodide I 131 Capsules Diagnostic is indicated for use in adults for:

  • Assessment of thyroid function using radioactive iodine (RAI) uptake test
  • Imaging the thyroid (scintigraphy)

Sodium Iodide, i-123 Dosage and Administration

Radiation Safety

Sodium Iodide I 131 Capsules Diagnostic is a radioactive drug and should be handled with appropriate safety measues to minimize radiation exposure to the patient and healthcare worker [see Warnings and Precautions (5.2)].

  • Use waterproof gloves during the entire handling and administration procedure.
  • Maintain adequate shielding during the life of the product
  • Measure patient dose by a suitable radioactivity calibration system immediately prior to administration.

Recommended Dosage and Administration Instructions

Administer Sodium Iodide I 131 Capsules Diagnostic orally prior to scanning. The recommended dose of Sodium Iodide I 131 Capsules Diagnostic for an adult patient is the following:

  • Thyroid Function: 0.185 to 1.1 megabecquerels (MBq) [5 to 30 microcuries (microCi)]. Administer 24 hours before uptake measurement.
  • Thyroid Imaging (Scintigraphy): 1.85 to 3.70 MBq (50 to 100 microCi). Administer 16 -24 hours before imaging.

Consult the color-coded decay calendar that is updated in January of every year to determine which colored capsule(s) correspond to the prescribed dose: http://www.draximage.com/data/PDF/118_en.pdf or calculate the correct dose from the date and time of calibration provided on the container label.

Prior to Sodium Iodide I 131 Capsules Diagnostic Administration

  • Obtain a pregnacy test in females of reproductive potential prior to administration to verify the absence of pregnancy [see Contraindications (4) and Use in Specific Populations (8.1, 8.3)].
  • Advise patients to maintain a low-iodine diet two weeks prior to radioiodine administration and continue for several days during the uptake or imaging process [see Drug Interactions (7)].
  • Advise patients to fast at least 2 hours before and 2 hours after administration to ensure absorption.
  • Advise patients to hydrate before and after administration of radioiodine and void frequently to ensure rapid excretion.

Radiation Dosimetry

The biokinetic and radiation dose distributions associated with thyroid uptake of iodide I 131 depend on dietary intake of stable iodine. A range of uptake percentages in an average adult (73.7 kg) are shown in Table 1. For a thyroid blocked from iodide uptake in the production of hormones, the effective half-life of iodide I 131 is approximately 1.4 hours; for low to high uptake, the effective half-life of I 131 ranges from approximately 80 to 90 hours.

Table 1 Absorbed dose per unit activity sodium iodide I 131 administered orally (mGy/MBq) in adult (73.7-kg reference model)
Organ Thyroid uptake of I 131 (% administered activity A0) 24 h after oral administration
Blocked thyroid
(0% A0)
Low uptake
(16% A0
Medium uptake
(26% A0)
High uptake
(36% A0)
Adrenals 0.044 0.051 0.055 0.059
Bone surfaces 0.030 0.089 0.12 0.16
Brain 0.021 0.093 0.13 0.17
Breast 0.020 0.038 0.048 0.058
Gallbladder wall 0.037 0.043 0.046 0.049
Gastrointestinal tract
Stomach wall 0.87 0.77 0.71 0.66
Small intestine wall 0.035 0.033 0.032 0.032
Colon wall 0.14 0.14 0.14 0.14
(Upper large intestine wall) 0.12 0.12 0.12 0.12
(Lower large intestine wall) 0.17 0.17 0.17 0.16
Heart wall 0.062 0.089 0.10 0.12
Kidneys 0.27 0.27 0.27 0.27
Liver 0.050 0.093 0.12 0.14
Lungs 0.053 0.10 0.13 0.15
Muscles 0.026 0.084 0.12 0.15
Oesophagus 0.024 0.10 0.14 0.19
Ovaries 0.038 0.037 0.036 0.035
Pancreas 0.060 0.064 0.066 0.068
Red marrow 0.031 0.072 0.095 0.12
Salivary glands 0.27 0.22 0.19 0.16
Skin 0.019 0.043 0.057 0.071
Spleen 0.064 0.069 0.072 0.075
Testes 0.025 0.024 0.023 0.22
Thymus 0.024 0.10 0.14 0.19
Thyroid 2.2 280 430 580
Urinary bladder wall 0.54 0.45 0.39 0.34
Uterus 0.045 0.042 0.040 0.038
Remaining organs 0.029 0.84 0.11 0.15
Effective dose per administered activity (mSv/MBq) 0.28 14 22 28

Dosage Forms and Strengths

Capsules: Each capsule contains 3.70 MBq (100 microCi) at time of calibration. Half of each capsule is white, while the other half is either pink, yellow, orange, grey or green according to the manufactured lot. The capsule will yield 2.03, 1.11, 0.61, or 0.33 MBq (55, 30, 16.5, or 9 microCi) according to the color-coded decay calendar which assigns a color and capsule activity for each week of the year. http://www.draximage.com/data/PDF/118_en.pdf

Table 2 below displays the (5) weeks activity of the capsule starting from the calibration day.

Table 2 Weekly Activity (MBq and microCi) of Each Capsule Starting from the Calibration Day
Week Activity (MBq) Activity (microCi)
1 3.70 100.0
2 2.03 54.9
3 1.11 30.0
4 0.61 16.5
5 0.33 8.9

Contraindications

Sodium Iodide I 131 Capsules Diagnostic is contraindicated in pregnancy [see Warnings and Precautions (5.1), Use in Specific Populations (8.1)].

Warnings and Precautions

Fetal Toxicity

Sodium Iodide I 131 Capsules Diagnostic is contraindicated in pregnancy because sodium iodide I 131 crosses the placenta and can cause severe and irreversible hypothyroidism in the neonate. Multiple reports in the literature describe neonatal hypothryroidism following in utero exposure to sodium iodide I 131. Some of these cases were severe and irreversible. Verify pregnancy status of females of reproductive potential prior to administering Sodium Iodide I 131 Capsules Diagnostic [see Use in Specific Populations (8.1, 8.3)].

Radiation Exposure

Sodium Iodide I 131 Capsules Diagnostic contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Follow safe administration instructions to minimize radiation exposure to the patient and healthcare providers [see Dosage and Administration (2.1)].

Risk of Radioactive Uptake Measurement and Imaging Misinterpretation

The recent intake of stable iodine in any form, or the use of thyroid or anti-thyroid drugs will affect the uptake of sodium iodide I 131. Question the patient carefully regarding their exposure to these drugs or procedures involving radiographic contrast media [see Drug Interactions (7)].

Hypersensitivity Reactions

Hypersensitivity reactions including anaphylaxis may occur in patients who receive sodium iodide I 131. Although iodine is not considered an allergen, hypersensitivity reactions may occur in relation with excipients or chemical component of the capsule, such as sodium thiosulfate. Obtain and document an allergy history, particularly a sulfite allergy. Emergency resuscitation equipment and personnel should be immediately available [see Adverse Reactions (6)].

Adverse Reactions

The following adverse reaction has been described elsewhere in the labeling:

  • Hypersensitivity Reactions [see Warnings and Precautions (5.4)]

The following adverse reactions have been identified during post-approval use from Sodium Iodide I 131 Capsules Diagnostic. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions associated with the administration of Sodium Iodide I 131 Capsules Diagnostic are:

  • Gastrointestinal disorders: vomiting, nausea, and diarrhea
  • General disorders and administration site conditions: local thyroid swelling
  • Immune system disorders: hypersensitivity reactions
  • Skin and subcutaneous tissue disorders: itching, rash, hives, and erythema

Drug Interactions

Certain drugs and iodine-containing foods interfere with the accumulation of radioiodide by the thyroid. Review the patients history, current medications, and recent diagnostic tests prior to the administration of Sodium Iodide I-131 Capsules Diagnostic. Advise patients to maintain a low-iodine diet two weeks prior to radioiodine administration and continue for several days during the uptake or imaging process and to discontinue the following products before they undergo the procedure as shown in Table 3:

Table 3 Pharmaceuticals/OTCs/Agents Blocking Radioiodine Uptake
​Products Recommended duration of withdrawal
Thionamide medications
(e.g., propylthiouracil, methimazole carbimazole)
3 days
Multivitamins containing iodide 10 days
Natural or synthetic thyroid hormones
triiodothyronine
thyroxine

2 weeks

4 weeks

Iodine containing foods: iodinized salt, dairy products, egg yolks, seafood, turkey, and liver 2 weeks
Kelp, agar, carrageenan, Lugol solution 3 weeks
Saturated solution of potassium iodide 3 weeks
Topical iodine
(e.g., surgical skin preparation)
3 weeks
Radiographic contrast agents
Water soluble
Lipophilic

2 months

6 months

Amiodarone 6 months

USE IN SPECIFIC POPULATIONS

Enter section text here

Pregnancy

Risk Summary
Sodium Iodide I 131 Capsules Diagnostic is contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible. Data from the published literature describe reports of neonatal thyroid abnormalities after fetal exposure, including agenesis of the thyroid and hypothyroidism (see Clinical Considerations, Data). No animal reproductive studies have been conducted.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.

Clinical Considerations
Fetal/Neonatal Adverse Reactions
A fetus exposed to sodium iodide I 131 can develop neonatal hypothyroidism. Delay in diagnosis of neonatal hypothyroidism after exposure to sodium iodide I 131 in utero can result in severe sequelae such as decreased mental capacity and delayed skeletal maturation. Monitor thyroid function in any infant born after in utero exposure to sodium iodide I 131.

Data
Human Data
Literature reports of maternal exposures to sodium iodide I 131 at doses of 330-8300 MBq during 4-26 weeks estimated gestational age. There were various adverse pregnancy outcomes; the most common was hypothyroidism in infants and children.

Lactation

Risk Summary
Advise women to discontinue breastfeeding after administration of Sodium Iodide I 131 Capsules Diagnostic. Infant exposure to sodium iodide I 131 via breast milk is expected and may lead to hypothyroidism in the infant because sodium iodide I 131 in breast milk may reach concentrations equal to or greater than concentrations in maternal plasma (see Data).

Data
Published studies show that sodium iodide I 131 is transferred into breast milk and is taken up by the thyroid of the breastfed infant.

Females and Males of Reproductive Potential

Sodium Iodide I 131 is contraindicated in pregnancy because it causes fetal hypothyroidism [see Use in Specific Populations (8.1) and Warnings and Precautions (5.1)].

Pregnancy Testing
Obtain a pregnancy test in females of reproductive potential and verify the absence of pregnancy before administering Sodium Iodide I 131 Capsules Diagnostic [see Dosage and Administration (2.2)].

Pediatric use

Safety and efficacy in pediatric patients have not been established. Published reports suggest that the thyroid gland of pediatric patients is more sensitive to the adverse effects of sodium iodide I 131 (e.g., increased risk of radiation absorption).

Geriatric Use

Clinical experience has not identified differences in safety or effectiveness in geriatric patients compared to younger patients. However, elderly patients are more likely to have decreased renal function and radiation exposure is greater in patients with impaired renal function [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

Renal Impairment

Radiation exposure following Sodium Iodide I 131 Capsules Diagnostic is greater in patients with impaired renal function compared to patients with normal renal function [see Clinical Pharmacology (12.3)].

Overdosage

In the event of an overdosage of Sodium Iodide I 131 Capsules Diagnostic, monitor for thyroid suppression and consider administering a thyroid blocking agent (e.g. potassium iodide (KI) or perchlorate). Promote frequent voiding and encourage patients to maintain hydration to minimize radiation exposure.

Sodium Iodide, i-123 Description

Chemical Characteristics

Sodium Iodide I 131 Capsules Diagnostic is a radiodioactive diagnostic agent containing sodium iodide I 131 and supplied for oral administration in a gelatin capsule. Each capsule contains no-carrier-added sodium iodide I 131, disodium edetate dihydrate USP as a stabilizer, sodium thiosulfate pentahydrate USP as a reducing agent, and dibasic sodium phosphate anhydrous USP.

Sodium Iodide I 131 is designated chemically as Na131I and has a molecular weight of 153.99.

Physical Characteristics

Iodine I 131 decays by beta emission and associated gamma emission with a physical half-life of 8.04 days. The principal radiation emisions are listed in Table 4.

Table 4 Principal Radiation Emission Data from Decay of Sodium Iodide I 131
Radiation Mean % per Disintegration Mean Energy (keV) 
Beta-1 2.13% 69.4
Beta-3 7.20% 96.6
Beta-4 89.4% 191.6
Gamma-7 6.14% 284.3
Gamma-14 81.2% 364.5
Gamma-18 7.12% 637.0

External Radiation

The specific gamma-ray constant for iodine I 131 is 4.26 x 10-13 Cm2kg-1MBq-1s-1 (2.2 Rcm2/mCihr). The first half-value thickness of lead (Pb) for iodine I 131 is 0.27 cm. A range of values for the relative attenuation of the radiation emitted by iodine I 131 that results from interposition of various thicknesses of Pb is shown in Table 5. For example, the use of 2.59 cm of Pb will decrease the external radiation exposure by a factor of about 1,000.

Table 5 Radiation Attenuation of Iodine I 131 by Lead Shielding
Shield Thickness (Pb) cm Coefficient of Attenuation
0.27 0.5
0.56 0.25
0.99 10-1
2.59 10-2
4.53 10-3

To correct for physical decay of iodine I 131, the fractions that remain at selected intervals after the time of calibration are shown in Table 6.

Table 6 Physical Decay Chart: Iodine I 131, Half-Life 8.04 days
*
Calibration Time
0* 1.000 11 .388 22 .151
1 .918 12 .356 23 .138
2 .842 13 .327 24 .127
3 .773 14 .300 25 .116
4 .709 15 .275 26 .107
5 .651 16 .253 27 .098
6 .597 17 .232 28 .090
7 .548 18 .213 29 .083
8 .503 19 .195 30 .076
9 .461 20 .179
10 .423 21 .164

Sodium Iodide, i-123 - Clinical Pharmacology

Enter section text here

Mechanism of Action

Iodine is actively transported by the sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I+) which in turn iodinates tyrosine residues of thyroglobulin (tri or tetra-iodinated tyrosine). The gamma emission of Iodine I 131 is imaged or counted.

Pharmacokinetics

Absorption
Following oral administration of Sodium Iodide I 131 Capsules Diagnostic, 90% of the administered radioactivity of sodium iodide I 131 is systemically absorbed in the first 60 minutes.

Distribution
Following absorption, sodium iodide I 131 is distributed within the extra-cellular space. It is actively transported by the sodium-iodide symporter (NIS) proteinand binds to thyroglobulin resulting in accumulation in the thyroid. The thyroid uptake of iodide is usually increased in hyperthyroidism and in goiter, and is decreased in hypothyroidism. Sodium iodide I 131 also accumulates in the stomach, choroid plexus, salivary glands breast, liver, gall bladder, and kidneys.

Elimination
Metabolism
In thyroid follicular cells, iodide is oxidized through the action of thyroid peroxidase to iodinium (I+) which in turn iodinates tyrosine residues of thyroglobulin.

Excretion
Sodium iodide I 131 is excreted in urine and feces. The normal range of urinary excretion is 37% to 75% of the administered dose, varying with the thyroid and renal function of the patient. Fecal excretion is about 10%.

HOW SUPPLIED / STORAGE AND HANDLING

Enter section text here

How Supplied

Each capsule contains 3.70 megabecquerels (100 microCi) at time of calibration. Half of each capsule is white, while the other half is either pink, yellow, orange, grey or green according to the manufactured lot.

  • The capsules are packaged in plastic vials containing 5 capsules of the same strength and same color. The vials also contain one desiccant packet. (NDC 65174-461-05).
  • Consult the color-coded decay calendar that is updated in January of each year to help you establish which colored capsules correspond to your prescribed dose: http://www.draximage.com/data/PDF/118_en.pdf or calculate the correct dosage from the date and time of calibration provided on the container label.
  • The calibration date and expiration date are indicated on the vial container label.

Storage and Handling

Store Sodium Iodide I 131 Capsules Diagnostic between 15 °C and 30 °C (59 °F and 86 °F).

Store and dispose of Sodium Iodide I 131 Capsules Diagnostic in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.

This radiopharmaceutical is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.

Patient Counseling Information

Administration Instructions

  • Advise patients to hydrate before and after administration of Sodium Iodide I 131 Capsules Diagnostic and void frequently to ensure rapid excretion [see Dosage and Administration (2.2)].
  • Advise patients to fast at least 2 hours before and 2 hours after administration to ensure absorption [see Dosage and Administration (2.2)].
  • Advise patients to maintain a low-iodine diet two weeks prior to radioiodine administration and continue for several days during the uptake or imaging process [See Dosage and Administration (2.2) and Drug Interactions (7)].

Fetal Toxicity
Advise female patients of reproductive potential of the risk of neonatal hypothyroidism with fetal exposure [see Contraindications (4), Warnings and Precautions (5.1) and Use in Specific Populations (8.1, 8.3)].

Lactation
Advise women to discontinue breastfeeding after Sodium Iodide I 131 Capsules Diagnostic administration [see Use in Specific Populations (8.2)].

Manufactured by:
Jubilant DraxImage Inc., Kirkland, Québec, Canada, H9H 4J4.

PRINCIPAL DISPLAY PANEL - Capsule 3.7 MBq (Gray)

PRINCIPAL DISPLAY PANEL - Capsule 3.7 MBq (Yellow)

PRINCIPAL DISPLAY PANEL - Capsule 3.7 MBq (Orange)

PRINCIPAL DISPLAY PANEL - Capsule 3.7 MBq (Pink)

PRINCIPAL DISPLAY PANEL - Capsule 3.7 MBq (Green)

SODIUM IODIDE I 131 DIAGNOSTIC  
sodium iodide i 131 capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:65174-461
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Sodium Iodide I-131 (IODIDE ION I-131) IODIDE ION I-131 100 mCi
Inactive Ingredients
Ingredient Name Strength
Edetate Disodium  
Sodium Thiosulfate  
Sodium Phosphate, Dibasic, Anhydrous  
Product Characteristics
Color WHITE (one half is opaque white and other may be opaque pink, yellow, orange, grey or green) Score no score
Shape CAPSULE ( # 2) Size 18mm
Flavor Imprint Code
Contains         
Packaging
# Item Code Package Description
1 NDC:65174-461-05 5 CAPSULE in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA021305 05/01/2006
Labeler - Jubilant DraxImage Inc. (243604761)
Registrant - Jubilant DraxImage Inc. (243604761)
Establishment
Name Address ID/FEI Operations
Jubilant HollisterStier General Partnership 246762764 MANUFACTURE(65174-461)
Revised: 06/2016
 
Jubilant DraxImage Inc.
Hide